LTGOHealthcare · Biotechnology

LTGO Stock Forecast: Latigo Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$22

+2.83% on the day

The 4 Wall Street analysts covering Latigo Biotherapeutics, Inc. hold a median 12-month price target of $50 — +125.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 10 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$1.5B

Ticker Nerd rank

0 / 100

Median analyst target

$50

Analysts covering

Revenue$0.0

Operating income−$25.8M

Net income−$25.8M

Free cash flow−$21.4M

Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−1.5%

+19.6%

From high

−11.4%

From low

+21.4%

$18

$25

Range since 7 Aug 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

LTGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Latigo Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026

0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Growth

Accruals

Value

Momentum

Issuance

Quality

Volatility

Size (41): Smaller than most of the companies we track.

Volatility (0): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LTGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LTGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 7 Aug 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts

4 Buy0 Hold0 Sell

Low $36Median $50High $73

The green dot is the last close — the median target sits +125.7% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
1 Sept 2026	Guggenheim	Initiates	Buy	$50
1 Sept 2026	Jefferies	Initiates	Buy	$50
1 Sept 2026	Leerink Partners	Initiates	Outperform	$36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LTGO appears on the weeks it earns a place.

Performance

LTGO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

LTGO vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LTGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Latigo Biotherapeutics, Inc. (LTGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −9.1×
Price / sales: —
Price / book: −4.9×
EV / EBITDA: −15.8×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 47.1%
Return on assets: −144.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Latigo Biotherapeutics, Inc. (LTGO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Latigo Biotherapeutics, Inc. has a market value of $1.5B and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$95.5M.
Free cash flow in the twelve months to 30 June 2026: −$91.3M.
Shares outstanding: 60.2M.
Trailing P/E: −9.1×; forward P/E: −11.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Latigo Biotherapeutics, Inc. employs 66 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

LTGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
LTGOLatigo Biotherapeutics, Inc.	$1.5B	0
MAZEMaze Therapeutics, Inc.	$1.4B	24
ABSIAbsci Corp.	$1.4B	35
TYRATyra Biosciences, Inc.	$1.4B	31
AKTSAktis Oncology, Inc.	$1.3B	2
VORVor Biopharma, Inc.	$1.3B	15
TRAXFirst Tracks Biotherapeutics, Inc.	$1.3B	1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Latigo Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LTGO news & analysis

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 3 Sept 2026positive

Latigo Biotherapeutics reported its second quarter 2026 financial results, noting the completion of an upsized initial public offering that raised $397.4 million in gross proceeds, which together with existing cash is expected to fund operations into 2029. The company also highlighted the publication of positive onzotrigine abdominoplasty clinical trial results in The New England Journal of Medicine and the appointment of Naomi Lowy, M.D. as senior vice president of global regulatory affairs.

Why it matters — These developments signal extended financial runway, a key clinical validation from a top-tier publication, and strengthened regulatory expertise as Latigo advances its lead pain candidate.

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

24/7 Wall Street · 13 Aug 2026positive

Latigo Biotherapeutics (NASDAQ:LTGO) went public, receiving a strong reception from the market. The company is focused on developing a non-opioid pain treatment.

Why it matters — The IPO's warm welcome signals investor appetite for Latigo's non-opioid pain approach, making the company's public-market debut a notable event for LTGO watchers.

FAQ

Frequently asked questions about LTGO stock

What is the LTGO stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Latigo Biotherapeutics, Inc. have a median 12-month price target of $50, with estimates ranging from $36 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LTGO stock a buy right now?

Of the 4 analysts covering Latigo Biotherapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Latigo Biotherapeutics, Inc. 0 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LTGO?

As at 10 Sept 2026, Latigo Biotherapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (41 of 100).

Will LTGO stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +125.7% from the last close, and Ticker Nerd's factor model ranks Latigo Biotherapeutics, Inc. 0 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LTGO stock forecast for 2030?

No analyst covering Latigo Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $73 over the next 12 months.

What does Latigo Biotherapeutics, Inc. do?

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines.

What is the latest news on LTGO?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights". Latigo Biotherapeutics reported its second quarter 2026 financial results, noting the completion of an upsized initial public offering that raised $397.4 million in gross proceeds, which together with existing cash is expected to fund operations into 2029. The company also highlighted the publication of positive onzotrigine abdominoplasty clinical trial results in The New England Journal of Medicine and the appointment of Naomi Lowy, M.D. as senior vice president of global regulatory affairs.

Company

About Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs are built around NaV1.8 inhibitors, a class of compounds designed to interrupt pain signaling at its source while avoiding the addiction risks associated with opioid therapies. The company’s pipeline includes candidates for acute pain, chronic musculoskeletal pain, and broader acute and chronic pain applications, with oral and intravenous formulations in development. Latigo Biotherapeutics serves the pain-management market by advancing targeted therapies intended for use in settings such as postoperative care, musculoskeletal disorders, and other medically significant pain conditions. Headquartered in Thousand Oaks, California, the company operates within the biotechnology sector and is centered on creating differentiated treatments that address unmet needs in non-opioid pain control.

CEO Mr. Nima Farzan M.B.A. · 66 employees · United States · https://latigobio.com